Potential and Limits of Cannabinoids in Alzheimer's Disease Therapy

Overview

Journal Biology (Basel)

Publisher MDPI

Specialty Biology

Date 2021 Jul 2

PMID 34204237

Citations 29

Authors

Giulia Abate

Daniela Uberti

Simone Tambaro

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a detrimental brain disorder characterized by a gradual cognitive decline and neuronal deterioration. To date, the treatments available are effective only in the early stage of the disease. The AD etiology has not been completely revealed, and investigating new pathological mechanisms is essential for developing effective and safe drugs. The recreational and pharmacological properties of marijuana are known for centuries, but only recently the scientific community started to investigate the potential use of cannabinoids in AD therapy-sometimes with contradictory outcomes. Since the endocannabinoid system (ECS) is highly expressed in the hippocampus and cortex, cannabis use/abuse has often been associated with memory and learning dysfunction in vulnerable individuals. However, the latest findings in AD rodent models have shown promising effects of cannabinoids in reducing amyloid plaque deposition and stimulating hippocampal neurogenesis. Beneficial effects on several dementia-related symptoms have also been reported in clinical trials after cannabinoid treatments. Accordingly, future studies should address identifying the correct therapeutic dosage and timing of treatment from the perspective of using cannabinoids in AD therapy. The present paper aims to summarize the potential and limitations of cannabinoids as therapeutics for AD, focusing on recent pre-clinical and clinical evidence.

Citing Articles

Chronic exposure to a synthetic cannabinoid improves cognition and increases locomotor activity in Tg4-42 Alzheimer's disease mice.

Ott F, Sichler M, Bouter C, Enayati M, Wiltfang J, Bayer T J Alzheimers Dis Rep. 2025; 9:25424823241306770.

PMID: 40034517 PMC: 11869267. DOI: 10.1177/25424823241306770.

Mechanisms of comorbidity between Alzheimer's disease and pain.

Yao K, Wang S, Xu Z, Fan Z, Chen Z, Jia P Alzheimers Dement. 2025; 21(2):e14605.

PMID: 39998175 PMC: 11852355. DOI: 10.1002/alz.14605.

Exploring the diversity of cannabis cannabinoid and non-cannabinoid compounds and their roles in Alzheimer's disease: A review.

Doumar H, Mostafi H, Elhessni A, Touhami M, Mesfioui A IBRO Neurosci Rep. 2025; 18:96-119.

PMID: 39866750 PMC: 11763173. DOI: 10.1016/j.ibneur.2024.12.011.

The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment.

Keck A, Scheuermann J, Scheerbaum P, Graessel E, Muller-Vahl K BMC Complement Med Ther. 2025; 25(1):19.

PMID: 39844123 PMC: 11755935. DOI: 10.1186/s12906-025-04753-w.

Multiple Roles of Apolipoprotein E4 in Oxidative Lipid Metabolism and Ferroptosis During the Pathogenesis of Alzheimer's Disease.

Faraji P, Kuhn H, Ahmadian S J Mol Neurosci. 2024; 74(3):62.

PMID: 38958788 PMC: 11222241. DOI: 10.1007/s12031-024-02224-4.

References

Oliveira da Cruz J, Robin L, Drago F, Marsicano G, Metna-Laurent M . Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse. Neuroscience. 2015; 323:35-42. DOI: 10.1016/j.neuroscience.2015.05.002. View

Jayamanne A, Greenwood R, Mitchell V, Aslan S, Piomelli D, Vaughan C . Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol. 2005; 147(3):281-8. PMC: 1751298. DOI: 10.1038/sj.bjp.0706510. View

Woelfl T, Rohleder C, Mueller J, Lange B, Reuter A, Schmidt A . Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Emotion, Cognition, and Attention: A Double-Blind, Placebo-Controlled, Randomized Experimental Trial in Healthy Volunteers. Front Psychiatry. 2020; 11:576877. PMC: 7693539. DOI: 10.3389/fpsyt.2020.576877. View

Aso E, Sanchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I . Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. J Alzheimers Dis. 2014; 43(3):977-91. DOI: 10.3233/JAD-141014. View

Piro J, Benjamin D, Duerr J, Pi Y, Gonzales C, Wood K . A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep. 2012; 1(6):617-23. PMC: 3715876. DOI: 10.1016/j.celrep.2012.05.001. View

Brown K, Laun A, Song Z . Cannabidiol, a novel inverse agonist for GPR12. Biochem Biophys Res Commun. 2017; 493(1):451-454. PMC: 5849771. DOI: 10.1016/j.bbrc.2017.09.001. View

Rempel V, Volz N, Glaser F, Nieger M, Brase S, Muller C . Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. J Med Chem. 2013; 56(11):4798-810. DOI: 10.1021/jm4005175. View

Li Y, Kim J . CB2 Cannabinoid Receptor Knockout in Mice Impairs Contextual Long-Term Memory and Enhances Spatial Working Memory. Neural Plast. 2016; 2016:9817089. PMC: 4706977. DOI: 10.1155/2016/9817089. View

Cravatt B, Demarest K, Patricelli M, Bracey M, Giang D, Martin B . Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001; 98(16):9371-6. PMC: 55427. DOI: 10.1073/pnas.161191698. View

10.

Bilkei-Gorzo A . The endocannabinoid system in normal and pathological brain ageing. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607):3326-41. PMC: 3481530. DOI: 10.1098/rstb.2011.0388. View

11.

Johnson D, Stiff C, Lazerwith S, Kesten S, Fay L, Morris M . Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011; 2(2):91-96. PMC: 3109749. DOI: 10.1021/ml100190t. View

12.

Hill J, Zuluaga-Ramirez V, Gajghate S, Winfield M, Sriram U, Rom S . Activation of GPR55 induces neuroprotection of hippocampal neurogenesis and immune responses of neural stem cells following chronic, systemic inflammation. Brain Behav Immun. 2018; 76:165-181. PMC: 6398994. DOI: 10.1016/j.bbi.2018.11.017. View

13.

Currais A, Quehenberger O, Armando A, Daugherty D, Maher P, Schubert D . Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. NPJ Aging Mech Dis. 2017; 2:16012. PMC: 5514994. DOI: 10.1038/npjamd.2016.12. View

14.

Hill M, Froc D, Fox C, Gorzalka B, Christie B . Prolonged cannabinoid treatment results in spatial working memory deficits and impaired long-term potentiation in the CA1 region of the hippocampus in vivo. Eur J Neurosci. 2004; 20(3):859-63. DOI: 10.1111/j.1460-9568.2004.03522.x. View

15.

Saliba S, Jauch H, Gargouri B, Keil A, Hurrle T, Volz N . Anti-neuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells. J Neuroinflammation. 2018; 15(1):322. PMC: 6240959. DOI: 10.1186/s12974-018-1362-7. View

16.

Zilka N, Kazmerova Z, Jadhav S, Neradil P, Madari A, Obetkova D . Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation. 2012; 9:47. PMC: 3334709. DOI: 10.1186/1742-2094-9-47. View

17.

Hanus L, Meyer S, Munoz E, Taglialatela-Scafati O, Appendino G . Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016; 33(12):1357-1392. DOI: 10.1039/c6np00074f. View

18.

KOE B, Milne G, Weissman A, Johnson M, Melvin L . Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics. Eur J Pharmacol. 1985; 109(2):201-12. DOI: 10.1016/0014-2999(85)90421-2. View

19.

Levar N, Francis A, Smith M, Ho W, Gilman J . Verbal Memory Performance and Reduced Cortical Thickness of Brain Regions Along the Uncinate Fasciculus in Young Adult Cannabis Users. Cannabis Cannabinoid Res. 2018; 3(1):56-65. PMC: 5870060. DOI: 10.1089/can.2017.0030. View

20.

Schubert D, Kepchia D, Liang Z, Dargusch R, Goldberg J, Maher P . Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer's Disease. Mol Neurobiol. 2019; 56(11):7719-7730. PMC: 6815693. DOI: 10.1007/s12035-019-1637-8. View